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Thrombin plays a central role in normal and abnormal
hemostatic processes. It is assumed that a-thrombin ac-
tivates platelets by hydrolyzing the protease-activated
receptor (PAR)-1, thereby exposing a new N-terminal
sequence, a tethered ligand, which initiates a cascade of
molecular reactions leading to thrombus formation.
This process involves cross-linking of adjacent platelets
mediated by the interaction of activated glycoprotein
(GP) IIb/IIIa with distinct amino acid sequences, LG-
GAKQAGDV and/or RGD, at each end of dimeric fibrin-
ogen molecules. We demonstrate here the existence of a
second a-thrombin-induced platelet-activating path-
way, dependent on GP Ib, which does not require hy-
drolysis of a substrate receptor, utilizes polymerizing
fibrin instead of fibrinogen, and can be inhibited by the
Fab fragment of the monoclonal antibody LJIb-10 bound
to the GP Ib thrombin-binding site or by the cobra
venom metalloproteinase, mocarhagin, that hydrolyzes
the extracellular portion of GP Ib. This alternative
a-thrombin pathway is observed when PAR-1 or GP IIb/
IIIa is inhibited. The recognition sites involved in the
cross-linking of polymerizing fibrin and surface inte-
grins via the GP Ib pathway are different from those
associated with fibrinogen. This pathway is insensitive
to RGDS and anti-GP IIb/IIIa antibodies but reactive
with a mutant fibrinogen, g407, with a deletion of the
g-chain sequence, AGDV. The reaction is not due to sim-
ple trapping of platelets by the fibrin clot, since ligand
binding, signal transduction, and second messenger for-
mation are required. The GP Ib pathway is accompanied
by mobilization of internal calcium and the platelet re-
lease reaction. This latter aspect is not observed with
ristocetin-induced GP Ib-von Willebrand factor aggluti-
nation nor with GP Ib-von Willebrand factor-polymeriz-
ing fibrin trapping of platelets. Human platelets also
respond to g-thrombin, an autoproteolytic product of
a-thrombin, through PAR-4. Co-activation of the GP Ib,
PAR-1, and PAR-4 pathways elicit synergistic responses.
The presence of the GP Ib pathway may explain why
anti-a-thrombin/anti-platelet regimens fail to com-
pletely abrogate thrombosis/restenosis in the cardiac
patient.
Despite advances in anti-platelet and anti-thrombotic treat-
ment regimens, cardiovascular diseases remain the leading
cause of death in the United States (1). Clinically employed
anti-platelet and anti-thrombotic agents include heparin, aspi-
rin (2), integrilin (3), and anti-GP1 IIb/IIIa antibodies (c7E3
Fab, abciximab, or, ReoPro) (4, 5). a-Thrombin, generated at
the site of vessel injury, is generally assumed to catalyze the
hydrolysis of an N-terminal peptide from the human platelet
seven-transmembrane thrombin receptor, protease-activated
receptor 1 (PAR-1), which initiates a cascade of molecular re-
actions leading to thrombus formation. Thrombin-induced ac-
tivation of PAR-1, as for other agonist-activated platelet recep-
tors, results in an outside-in signal transduced process followed
by the alteration of the surface integrin, GP IIb/IIIa, by an
inside-out signal (6). The conformational change of GP IIb/IIIa
leads to the Ca21-dependent binding of the bifunctional fibrin-
ogen molecule (7). The fibrinogen-GP IIb/IIIa binding sites
recognize RGDX sequences on the fibrinogen a-chains and an
LGGAKQAGDV sequence on the g-chains (8). Potential com-
peting peptides of RGDS and peptides including the g sequence
LGGAKQAGDV were found to be effective antagonists of plate-
let aggregation (9). Anti-GP IIb/IIIa antibodies such as c7E3
Fab (4, 5) and LJ-CP8 (10) are also potent inhibitors of fibrin-
ogen binding to this glycoprotein complex in activated plate-
lets. Early studies of the cellular thrombin receptor indicated
that more than one species exist in platelets (11, 12). Many
questions related to the identity and mechanism(s) of action of
the platelet thrombin receptor(s) were resolved with the clon-
ing and sequencing of PAR-1 (13). Human platelets appear to
respond to PAR-1 and a second minor receptor PAR-4 (14–16),
while the recently cloned PAR-3 (17) is either absent or present
in only trace amounts. Mouse platelets, on the other hand,
respond to a-thrombin primarily through PAR-3 and, second-
arily, PAR-4, with no involvement of PAR-1 (14). Other impor-
tant issues still remain unresolved with regard to the PARs.
Another platelet membrane protein, GP Ib, may also function,
in part, as a thrombin receptor (11, 12, 18–21). A major role of
GP Ib, complexed with GP IX, is the specific interaction with
subendothelium-bound von Willebrand factor (vWF) under
high shear rates to facilitate platelet adhesion to injured vas-
cular walls (22). The expression on the plasma membrane of
the vWF receptor, GP Ib, requires the stable expression of GP
Ibb, GP Iba, and GP IX (23). The GP Ib-IX complex associates* The costs of publication of this article were defrayed in part by the
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with the cytoskeletal actin-binding protein via the cytoplasmic
domain of GP Iba (24, 25). This GP Iba-actin-binding protein
association is initiated by the binding of vWF to GP Ib and
appears to be linked to vWF-induced transmembrane signaling
(25). Signal transduction appears to be regulated, at least in
part, by one form of the 14-3-3 z protein (26) and its association
with the GP Ib-IX-V complex (27). The GP Ib receptor also
possesses a thrombin binding site that may respond to lower
concentrations of thrombin than required to activate the PARs
(11, 12). The GP Ib-thrombin complex may serve to prime the
activation of PAR-1 as the thrombin levels rise (11, 18). The
physiologic roles of the three purported platelet thrombin re-
ceptors have yet to be clearly defined. While an in vitro func-
tional role of PAR-1 has been demonstrated for a-thrombin-
induced platelet aggregation (13), no comparable response has
ever been described for PAR-4 or GP Ib with a natural throm-
bin agonist.
We demonstrate here the existence of two thrombin recep-
tors on human platelets that respond to a-thrombin. One is the
PAR-1 receptor, and the second is GP Ib. Unlike the activation
of platelets via PAR-1, activation by the GP Ib pathway does
not require thrombin hydrolysis of the substrate receptor, uti-
lizes polymerizing fibrin instead of fibrinogen, and is inhibited
by the Fab fragment of the monoclonal antibody LJIb-10 that
specifically binds to the GP Ib thrombin-binding site (28). This
alternative pathway is readily observed in the presence of
PAR-1 or GP IIb/IIIa inhibitors. Human platelets also respond
to g-thrombin, the autoproteolytic product of a-thrombin,
through activation of a second protease-activated receptor,
PAR-4. Co-activation of the GP Ib, PAR-1, and PAR-4 pathways
elicits synergistic responses.
EXPERIMENTAL PROCEDURES
Materials—The a-thrombin was initially obtained from Ortho Diag-
nostic Systems (Raritan NJ), as Fibrindex. Production of Fibrindex was
discontinued, and a-thrombin was subsequently obtained from Chro-
nolog Corp. (Havertown, PA). The two products at 0.05–0.1 units/ml
gave identical results. The g-thrombin was obtained from Hematologic
Technologies. The thrombin receptor-activating peptide for PAR-1
(TRAP-1), SFLLRNP, was synthesized by TANA Laboratories (Hous-
ton, TX), and peptides for PAR-4, GYPGQV (TRAP-4) and AYPGKF
(TRAP-4A), were supplied from the Schering-Plough stocks. The anti-
PAR-1 drug, SCH203099, was also supplied by Schering-Plough. Hu-
man fibrinogen, RGDS, GPRP-amide, and the water-soluble serine
protease inhibitor, 4-[2-aminoethyl]-benzene sulfonyl fluoride (AEBSF)
were purchased from Sigma. The thrombin substrate CBS 34.47 came
from Diagnostica Stago-American Bioproducts. Fura-2 AM was pur-
chased from Molecular Probes, Inc. (Eugene, OR). The ristocetin and
Chrono-lume (luciferin-luciferase) were obtained from Chronolog Corp.
Anti-PAR-1 antibodies were kindly supplied by Drs. Greco and Jamie-
son (polyclonal antibody that recognizes the sequence LLRNPND-
KYEPF) and Dr. Brass (monoclonal antibody ATAP-2). The anti-GP
IIb/IIIa antibody c7E3 Fab was a kind gift from Dr. Coller. All other
anti-GP Ib and anti-GP IIb/IIIa antibodies employed along with the
recombinant fibrinogens were from our laboratories. The cobra metal-
loproteinase, mocarhagin, from Naja mocambique mocambique was
kindly supplied by Dr. Berndt (Baker Medical Research Institute,
Victoria, Australia). The concentrations and conditions employed with
all reagents are described throughout.
Platelet Preparation—Blood was drawn by venipuncture into plastic
tubes that contained 1⁄10 volume of 3.8% citrate and platelet-rich plasma
(PRP) prepared as previously described (29). Blood samples were ob-
tained from healthy graduate student donors who were medication-free
and signed informed consent forms approved by the institutional hu-
man studies committee. Washed platelets were prepared from the PRP
as previously described (30). Briefly, PRP was diluted with 3 volumes of
100 mM citrate buffer (pH 6.0) plus 1–2 volumes of Hepes-Tyrode buffer,
pH 7.4, final volume 50 ml; pelleted; and resuspended in Hepes-Tyrode
buffer (136 mM NaCl, 2.7 mM KCl, 3.3 mM NaH2PO4, 10 mM MgCl2, 3.8
mM Hepes, pH 7.4) with 1 mg/ml dextrose plus 1 mg/ml bovine serum
albumin at 2–3 3 105/ml or at a l03 normal concentration of 2–3 3
106/ml.
Platelet Aggregation—Platelet aggregations were performed on a
dual channel Chronolog lumiaggregometer (Chronolog Corp.) as previ-
ously described (31). Aggregations were conducted with 480 ml of
washed platelets or a 50-ml sample of the concentrated platelets added
to 430 ml of Hepes-Tyrode buffer with a final platelet count of 2–3 3
105/ml. Agonists and inhibitors were added as detailed throughout with
the concentration of the reagents noted. In some experiments, the
a-thrombin plus fibrinogen was added to the platelets, while in others
the order of addition was reversed. This reversal of order allowed for the
generation of polymerizing fibrin prior to the addition of the platelets.
Calcium Mobilization—The mobilization of internal stores of cal-
cium, [Ca21]i, was monitored with a Hitachi F-2000 fluorescence spec-
trophotometer as previously reported (32) in the presence of extracel-
lular EGTA to chelate extracellular Ca21. Platelets, as PRP, were
preloaded with 1 mM Fura-2/AM for 45–60 min and then washed and
resuspended in Hepes-Tyrode buffer as described above, at a 103 con-
centration. Samples were incubated, at room temperature, with or
without 10 mM SCH203099 for 1 h prior to analysis. A 50-ml sample of
platelets was added to 430 ml of Hepes-Tyrode buffer in a special quartz
microcuvette with a 4.5-mm path length with stirring at 37 °C. Agonists
were added through an injection port at the levels described. Excitation
wavelengths were 340 and 380 nm, and emission was measured at 505
nm. Calibration and conversion of raw data were performed exactly as
reported (32).
ATP Release—The platelet release reaction was monitored simulta-
neously, in some experiments, with aggregation as previously reported
(33). The release of dense granule ATP from aggregating platelets was
detected as light emission in the Chronolog lumiaggregometer produced
by the reaction of ATP with luciferin catalyzed by luciferase
(Chrono-lume).
Fluorescence-activated Cell Sorting Analysis—Platelets were washed
in cold phosphate-buffered saline containing 0.1% (w/v) bovine serum
albumin and 15 mM NaN3 (Buffer) for 5 min at 1200 3 g. Pellets were
resuspended and washed once, and the pellet was resuspended in 1 ml
of room temperature Buffer. Platelets were incubated with 20 ml of
antibody at 20 mg/ml for 40 min at 4 °C, washed once in Buffer, and
incubated with 20 ml of secondary fluorescein isothiocyanate-conju-
gated goat anti-mouse antibody (1:40 dilution) for 30 min at 4 °C. Then
platelets were washed as above, resuspended in 1 ml of count solution,
and analyzed for fluorescence in a FACSort flow cytometer (Becton
Dickinson, San Jose, CA) using the Lysis II software program. An
acquisition in a live gate containing the platelets and excluding red
blood cells and debris was performed.
Electron Microscopy—Platelet aggregations were performed as de-
scribed above and monitored in the aggregometer. A 300-ml sample of
Trump’s EM fixative (1% glutaraldehyde plus 4% formaldehyde) was
added to the 500-ml aggregated platelet sample and incubated for 5 min.
Samples were then pelleted at 4000 rpm for 5 min in a microcentrifuge,
and the pellet was fixed with Trump’s EM fixative. Samples were
postfixed with OsO4 and embedded in epon, and sections were stained
with uranyl acetate and lead citrate.
RESULTS
The experiments described here indicate that an a-thrombin-
GP Ib interaction may induce a distinct pathway of platelet
aggregation and, along with PAR-1 and PAR-4, may be func-
tionally relevant. a-Thrombin (0.05–0.1 units/ml) and the pep-
tide SFLLRNP, the PAR-1 TRAP-1, induced platelet aggrega-
tion with similar kinetics (Fig. 1, A (a) and B (a)). An equivalent
amount of g-thrombin (10–20 nM, comparable with the activity
of 0.05–0.1 units/ml a-thrombin) induced platelet aggregation
with distinctly slower kinetics but a similar end point (Fig. 1C
(a)), as did the PAR-4 thrombin receptor-activating peptide
(TRAP-4), GYPGQV (Fig. 1D (a)). Platelets that had been pre-
incubated with an anti-PAR-1 antibody (either a polyclonal
antibody that recognizes the sequence LLRNPNDKYEPF or
the monoclonal antibody ATAP-2 (34); only results with the
latter are shown) or treated with a chemically defined PAR-1
inhibitor, SCH203099 (35), had a delayed aggregation profile
relative to controls when stimulated with a-thrombin but ulti-
mately reached a similar level of aggregation (Fig. 1, A (e) and
E (a), respectively). SCH203099 at 5–10 mM did not inhibit
platelet activation induced by 1 mM TRAP-4 or 10–30 nM
g-thrombin (Fig. 1, G and H); however, TRAP-1-induced aggre-
gation was completely inhibited but not platelet shape change
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(Fig. 1F). Total inhibition of platelet aggregation was main-
tained for greater than 15 min, at which time monitoring
ceased. Platelets treated with SCH203099 (7.5 mM) plus
ATAP-2 (50 mg/ml) have the PAR-1 receptor blocked at two
levels: at the tethered ligand, blocking hydrolysis by a-throm-
bin, and at the PAR-1 receptor site for the tethered ligand or
synthetic TRAP-1. These platelets still responded to a-throm-
bin after a delay period (Fig. 1E (e)), suggesting the presence of
another receptor. The complete inhibition of platelet aggrega-
tion upon the addition of the Fab fragment of the anti-GP Ib
antibody, LJIb-10, (binds to the GP Ib thrombin binding site) to
the SCH203099 plus ATAP-2-treated platelets indicates that
GP Ib is the second a-thrombin receptor (Fig. 1E (g)).
The potential presence of three distinct thrombin receptors
on human platelets could be defined with combinations of in-
hibitors and PAR-4 desensitization. Platelets preincubated for
1 h with 350–700 mM TRAP-4, under nonstirring conditions,
could not be activated by subsequent additions of 10 nM
g-thrombin or TRAP-4 at mM concentrations (Fig. 1, C (b) and
D (b)). Identical results were obtained with the more reactive
PAR-4-activating peptide, AYPGKF (TRAP-4A) (36). Control
platelets aggregated optimally with 100 mM TRAP-4A. Platelets
FIG. 1. Platelet aggregation induced by a-thrombin, g-thrombin, or TRAPs in the presence or absence of specific inhibitors.
Washed platelets were treated or untreated with 5–10 mM SCH203099, a PAR-1 inhibitor, for 1–2 h. Representative curves of several experiments
are shown for each test condition. Curves labeled a in panels A–D are with control platelets (50 ml) added to 430 ml of Hepes-Tyrode buffer, plus
5 ml of fibrinogen (final concentration 100 mg/ml) plus a-thrombin (a-T, 0.05 NIH units/ml) (A); TRAP-1 (7.6 mM) (B); g-thrombin (g-T, 10 nM) (C);
and TRAP-4 (1 mM) (D). Curves labeled a in panels E–H are with SCH203099-treated platelets, using the same conditions as in A–D. Listed below
each panel for the curves labeled a are the percent mean aggregation (Agg), slope measured for the major portion of the aggregation curve (grid
divisions/min; 1 grid division equals 1.25% aggregation), and t5O (min). S.D. and number of determinations (in parentheses) are shown for each
measurement. The t50 for control samples is the time required to reach 50% of maximal aggregation; for treated samples, it is the time required
to reach a level of aggregation equivalent to the control t50. Representative results obtained with different inhibitors of platelet function are shown
in selected panels. Control platelets (without antibody or drug) were preincubated with subaggregating concentrations (350–700 mM) of TRAP-4
(GYPGQV) to desensitize PAR-4 prior to the addition of a-thrombin (curve b in panel A), g-thrombin (curve b in panel C), or TRAP-4 (curve b in
panel D). Results with control platelets treated simultaneously with TRAP-1 plus 200 mM RGDS (c) or 1.2 mM GPRP (d) are presented in panel B.
In panel E, SCH203099-treated platelets were incubated, prior to the addition of a-thrombin, with ATAP-2 (50 mg/ml) (e), ATAP-2 plus a
subaggregating concentration of TRAP-4 (f), or ATAP-2 plus 50 mg of the Fab fragment of the anti-GP Ib antibody, LJIb-10 (Fab-10) (g). Control
platelets treated with ATAP-2 are shown in panel A (e). Curves labeled with the same lowercase letter represent an equivalent experimental
condition with each agonist.
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incubated for 20 min with suboptimal concentrations of
TRAP-4A (30 mM) were totally unreactive with 100 mM
TRAP-4A or 10 nM g-thrombin but were fully aggregated upon
the addition of 0.1 units/ml a-thrombin (data not shown). Fur-
thermore, control platelets and platelets treated with
SCH203099 plus ATAP-2 that were preincubated with TRAP-4
still aggregated upon the addition of a-thrombin (Fig. 1, A (b)
and E (f), respectively). This evidence indicates that TRAP-4
and g-thrombin activate PAR-4, while a-thrombin activates
PAR-1 and a third receptor.
Further evidence for the presence of a thrombin-GP Ib plate-
let aggregation pathway comes from studies with the cobra
venom metalloproteinase, mocarhagin, which has been shown
to hydrolyze the extracellular portion of GP Ib that contains the
vWF and thrombin binding domains (37). Concentrated plate-
let samples were incubated with 5–20 mg/ml mocarhagin for
60–90 min at 37 °C in the absence or presence of SCH203099
and/or Fab LJ Ib-10 (Fab-10). Mocarhagin (20 mg/ml for 90 min)
alone did not alter the slope or extent of platelet aggregation
induced by the PAR-1 or PAR-4 agonists, TRAP-1 or g-throm-
bin, respectively (Fig. 2A). However, in a dose- and time-de-
pendent fashion, mocarhagin significantly inhibited a-throm-
bin-induced aggregation of platelets simultaneously incubated
with the PAR-1 inhibitor, SCH203099. Fig. 2B is representa-
tive of three different experiments where 10 mM SCH203099
plus 20 mg/ml mocarhagin inhibited a-thrombin-induced plate-
let aggregation ;100% for the first 3 min with the eventual
slow aggregation phase occurring at the 3–6-min point after
the addition of a-thrombin. The delayed aggregation appears to
be due to residual intact GP Ib molecules on the platelet sur-
face as demonstrated by fluorescence-activated cell sorting
analysis (Fig. 2C). The combined addition of SCH203099 plus
Fab-10 and mocarhagin essentially abrogated any delayed ag-
gregation phase in the first 7 min (Fig. 2B).
We reasoned that GP Ib may be the third thrombin receptor
that, along with PAR-1, is involved in the a-thrombin-induced
activation of platelets. In this regard, we hypothesized that the
1–2-min delay in aggregation observed with platelets treated
with anti-PAR-1 antibody or SCH203099 may correspond to
the time required for the generation of polymerizing fibrin,
which could then participate in platelet aggregation in a man-
ner different from fibrinogen, as previously reported (38 39).
This alternative a-thrombin pathway would normally be ob-
scured by the action of the rapidly acting PAR-1 pathway. We
further hypothesized that a-thrombin-induced aggregation via
the PAR-1 pathway, as depicted in Fig. 1A, is entirely, or pre-
dominantly, dependent upon fibrinogen-platelet interactions.
Initial studies with TRAP-1-induced platelet aggregation
demonstrated that the PAR-1 pathway was blocked by RGDS
but little affected by GPRP-amide (Sigma), an inhibitor of
fibrin polymerization (Fig. 1, B (c) and B (d), respectively).
Thus, we tested the hypothesis that an alternate thrombin-
induced pathway is associated with platelet aggregation medi-
ated by polymerizing fibrin in lieu of native fibrinogen. Washed
platelets (50 ml), as a 103 concentrate, were added to 0.05–0.1
units/ml a-thrombin plus fibrinogen preincubated for 2 min
(polymerizing fibrin) in 430 ml of buffer. The kinetics of aggre-
gation with thrombin plus polymerizing fibrin (Fig. 3B (a)) was
essentially the same as that seen with thrombin plus fibrino-
gen added simultaneously to platelets (Fig. 3A (a)). Aggrega-
tion in the presence of polymerizing fibrin was little affected by
RGDS (Fig. 3D (a)). In contrast, the rapid onset a-thrombin-
induced PAR-1 pathway, seen in Fig. 3A (a), was inhibited by
the fibrinogen-competing peptide RGDS for the first few min-
utes, a time sufficient for the generation of polymerizing fibrin
(Fig. 3C (a)), after which aggregation ensued via the GP Ib
pathway, overriding the RGDS inhibition. The addition of
GPRP along with RGDS completely blocked platelet aggrega-
tion (Fig. 3, C (b) and D (b)), while the addition of GPRP alone
had little effect on a-thrombin-induced aggregation (Fig. 3A
(b)). A recombinant mutant fibrinogen (g407), lacking the
AGDV sequence in the g-chain required for GP IIb/IIIa-fibrin-
ogen interactions (40, 41), still supported a-thrombin-induced
platelet aggregation with normal kinetics, as did recombinant
wild type fibrinogen (data not shown). Aggregation via the
PAR-1 pathway was again initially blocked by the addition of
RGDS when g407 replaced normal fibrinogen, until g407 pre-
sumably began to polymerize (Fig. 3, compare E (a) and C (a)).
Residual adhering/endogenous fibrinogen cannot account for
the observed aggregation, since none occurred in the presence
of RGDS without added fibrinogen (Fig. 3E (c)). Aggregation
occurred with polymerizing g407 via the GP Ib pathway even in
the presence of RGDS (Fig. 3F) although at a reduced level.
RGDS completely blocked aggregation induced by U46619
and ADP, two agonists that cannot generate polymerizing fi-
brin (Fig. 3, G and H, without (a) versus with (b) RGDS) like
a-thrombin. When the thrombin inhibitor, hirudin, was added
FIG. 2. The role of GP Ib in a thrombin-induced platelet aggre-
gation pathway is elucidated by the action of mocarhagin, a
venom metalloproteinase that hydrolyzes GP Ib. A, control plate-
lets were incubated with or without 20 mg/ml mocarhagin, as described
under “Results,” followed by the addition of the PAR-1 or PAR-4 ago-
nist, TRAP-1 or g-thrombin (g-T), respectively. These same platelet
preparations were also incubated with or without 10 mM SCH203099 6
mocarhagin 6 Fab-10 prior to the addition of fibrinogen and a-throm-
bin. Results in panel B are representative of three different experi-
ments. The hydrolysis of platelet GP Ib by 5 and 20 mg/ml mocarhagin
was detected by fluorescence-activated cell sorting analysis with the
primary GP Ib-thrombin binding site-specific antibody, LJ Ib-10 (panel
C).
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to platelets (1–2 units/ml) followed by the addition of thrombin
plus fibrinogen, aggregation was completely inhibited (Fig. 5I).
If this inhibitor was added 2 min after fibrinogen was preincu-
bated with thrombin and then platelets were added 30 s later,
hirudin continued to prevent aggregation completely (Fig. 3B
(d)), indicating that polymerizing fibrin alone could not account
for the observed aggregations as platelet “trapping.” Electron
micrographic analysis was conducted with control platelets
FIG. 3. Role of polymerizing fibrin in platelet aggregation with normal or mutated fibrinogen. Platelet (Plt) aggregation was measured
as in Fig. 1 in the presence of fibrinogen (agonist added last) for curve a in panels A, C, E, G, and H or in the presence of polymerizing fibrin
(thrombin (0.05 units) plus fibrinogen (50 mg) (T 1 F) preincubated for 2 min in 430 ml of buffer prior to the addition of 50 ml of platelets) in panels
B, D, and F. In panel D, RGDS (200 mM) was added alone to polymerizing fibrin before the addition of platelets (a), or fibrin polymerization was
blocked by the addition of GPRP (1.2 mM), prior to the addition to RGDS (b). GPRP added at the same time as platelets, thrombin, and fibrinogen
had no effect on aggregation (panel A (b)). In panel C, fibrinogen and RGDS were added simultaneously to platelets followed by the addition of
a-thrombin, resulting in a delayed aggregation (a) or no aggregation results upon the addition of GPRP along with RGDS (b). Normal fibrinogen
is replaced by the mutant form, g407, in the presence of RGDS (panel E (a)). The omission of fibrinogen but the addition of RGDS does not support
any aggregation (panel E (c)). RGDS was added 2 min after g407 was preincubated with a-thrombin followed by platelets (panel F). Hirudin (1
unit/ml) added 2 min after thrombin and fibrinogen were mixed blocked aggregation (panel B (d)). Multiple determinations and numerical data for
the curves labeled a are reported below each panel, as in Fig. 1. Platelet aggregation studies were also conducted with the thromboxane A2 mimetic,
U46619 (1 mM), and washed platelets, without (a) or with (b) RGDS (panel G) or with ADP (10 mM) added to platelet-rich plasma without (a) or with
(b) RGDS (panel H).
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aggregated by a-thrombin (Fig. 4A) and with 10 mM
SCH203099-treated platelets added to polymerizing fibrin (fi-
brinogen plus a-thrombin preincubated for 2 min) (Fig. 4B) as
described in experiments above. The platelet aggregates of both
samples are indistinguishable and indicate true platelet aggre-
gation of the SCH203099-treated platelets in the presence of
polymerizing fibrin as opposed to platelet trapping.
Further studies were conducted to distinguish between
polymerizing fibrin-dependent platelet aggregation versus
platelet trapping. True platelet aggregation would presum-
ably involve signal transduction, second messenger forma-
tion with the subsequent mobilization of internal calcium,
and the platelet release reaction. On the other hand, platelet
trapping by the polymerizing fibrin should not involve any of
these secondary responses. Control and SCH203099-treated
platelets preloaded with Fura-2 were both shown to mobilize
internal calcium, [Ca21]i, in response to a-thrombin, while
only control platelets responded to TRAP-1 (Fig. 5A). The
mobilization of [Ca21]i was delayed in the SCH203099-
treated platelets, as compared with controls, in a fashion
similar to that observed with the kinetics of aggregation. The
platelet release reaction was monitored by release of dense
granule ATP. Here the release reaction was followed simul-
taneously with aggregation. Fig. 5, C and G, demonstrates
that drug-treated platelets aggregated under conditions de-
pendent upon polymerizing fibrin with equal amounts of ATP
released to the corresponding control samples that presum-
ably can aggregate independent of polymerizing fibrin (Fig. 5,
F and G; compared with control, Fig. 5, C and D). However,
conditions that induced platelet adhesion/polymerizing fi-
brin-trapping are not associated with any ATP release (Fig.
5, H–J). The ristocetin-induced adhesion/agglutination be-
tween platelets was dependent upon residual vWF present in
the washed platelet preparation. In some experiments, the
amount of residual vWF was too low to support this reaction
but could be replaced by the addition of 25 ml of PPP. In all
cases, no ATP was released (Fig. 5H). It has previously been
shown that polymerizing fibrin interacts with vWF-GP Ib
(42, 43). Results in Fig. 5J clearly demonstrate that this
interactive process resulted in an almost immediate trapping
of platelets in a clot without any release of ATP where hiru-
din was added after polymerizing fibrin was generated. The 1
unit/ml hirudin was sufficient to totally block a-thrombin-
induced platelet aggregation when added prior to fibrin for-
mation (Fig. 5I).
The serine protease inhibitor, AEBSF, completely inhibited
aggregation when added to thrombin prior to the addition of
fibrinogen and platelets (Fig. 6B). However, AEBSF did not
inhibit aggregation when added after the formation of the
thrombin-fibrin complex but prior to the addition of platelets
(Fig. 6C). These results imply that thrombin-induced aggrega-
tion via the GP Ib pathway requires thrombin interaction with
GP Ib but is independent of proteolytic activity at the receptor
site as long as polymerizing fibrin is present. AEBSF blocks the
catalytic site but not the GP Ib-binding site of thrombin, as
previously demonstrated with its analogue, phenylmethlylsul-
fonyl fluoride (44). Platelets were treated under identical con-
ditions with AEBSF plus the thrombin substrate, CBS 34.47
(7.5 mM) in order to determine if AEBSF remains active in the
presence of the polymerizing fibrin-thrombin complex. After a
5-min incubation, the platelets were pelleted in a microcentri-
fuge for 4 min at 14,000 rpm, and the generation of product was
monitored at 405 nm (30). AEBSF inhibited thrombin activity
in excess of 90%.
Significant synergistic responses were observed with subop-
timal doses of a-thrombin plus TRAP-4, as well as a-thrombin
plus g-thrombin or TRAP-1 plus TRAP-4 (Fig. 7, A–C). In all
cases, the sum of the aggregation induced by the individual
agonists at suboptimal concentrations varied between 0 and
15% (agonist concentrations varied between 0.01 and 0.005
units/ml for a-thrombin; between 0.1 and 2 nM for g-thrombin;
between 0.38 and 0.76 mM for TRAP-1; and between 175 and
350 mM for TRAP-4). Presumably, the low dose of a-thrombin
employed is below the level required to function/associate with
PAR-1 or PAR-4 but adequate to activate/bind to GP Ib.
TRAP-4 and g-thrombin appear to function only at PAR-4. To
demonstrate a synergistic mechanism between GP Ib and
PAR-4 and to exclude a role for PAR-1, platelets were incu-
bated with SCH203099 to inactivate PAR-1 (see Fig. 7D). The
SCH203099-treated platelets had a robust response with low
FIG. 4. Electron microscopic analysis of aggregated control
and SCH203099-treated platelets. Platelet aggregation was induced
by the addition of a-thrombin plus fibrinogen to control platelets (A),
while SCH203099 platelets were added after a-thrombin plus fibrino-
gen had been preincubated for 2 min as in Fig. 3. The original magni-
fication was 3 9450.
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dose a-thrombin plus TRAP-4 (Fig. 7E), but this synergistic
response was totally abrogated by the presence of Fab-10
(Fig. 7F).
DISCUSSION
Our studies reveal that three different thrombin receptors
exist on the surface of human platelets. Each appears to re-
spond to a- or g- thrombin under distinct conditions specific to
the individual receptor. Our results indicate that PAR-1 is not
functional in the presence of the anti-PAR-1 drug, SCH203099,
assuming that the physiologic tethered ligand and TRAP-1
have similar affinities for the receptor. Since drug reversal is
minimal in the time period studied, the a-thrombin response
FIG. 5. The mobilization of internal calcium, [Ca21]i, and release of dense granule ATP from activated platelets treated or
untreated with the PAR-1 inhibitor, SCH203099. The relative mobilization of [Ca21]i versus time (A) induced by 7.6 mM SFLLRNP (TRAP-1)
or 0.1 unit of a-thrombin/ml (a-T) is shown. The light lines are with control platelets, while the heavy dark lined graphs represent platelets treated
with 10 mM SCH203099. B–D and H–J are with control platelets, while E–G are with SCH203099-treated platelets. The concentrations of TRAP-1
and a-thrombin are as in A, and the concentrations of ristocetin and hirudin are 1.25 mg/ml and 2 units/ml, respectively. Fibrinogen (F) was added
to a final concentration of 100 mg/ml. The heavy dark curves in B–J represent platelet aggregation, while the light curves represent ATP release
as measured with luciferin-luciferase (Chrono-lume). The panels are representative of experiments performed at least in triplicate.
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observed with platelets preincubated with SCH203099 or the
monoclonal anti-PAR-1 antibody, ATAP-2, cannot be explained
by displacement of the antibody/drug and appears to be medi-
ated by another receptor. PAR-4 is not likely to be the alternate
receptor, because it is known to be insensitive to the low levels
of a-thrombin employed in our studies (14, 15). GP Ib, with its
FIG. 7. Synergistic effects of two
suboptimally acting agonists with
control and SCH203099-treated
platelets. Control platelet aggregation
with the agonists a-thrombin (a-T),
g-thrombin (g-T), TRAP-1, and TRAP-4
was titrated to determine agonist concen-
trations that yielded a response of 0–15%.
Agonist pairs, at these suboptimal con-
centrations, were then added, as indi-
cated, to control platelets (panels A–C) or
to SCH203099-treated platelets (panels
E–F). Panel D depicts results with
SCH203099-treated platelets plus
TRAP-1 alone, and panel F shows results
with platelets that were also preincu-
bated with 50 mg of the Fab fragment of
the anti-GP Ib monoclonal antibody
LJIb-10 (Fab-10) prior to the addition of
a-thrombin plus TRAP-4. The mean syn-
ergistically induced aggregation 6 S.D. is
reported in each panel as Agg(1), with the
number of determinations shown in pa-
rentheses. Agg(2) represents the mean ag-
gregation 6 S.D. of the agonists added
individually. The mean synergistic effect
is calculated as percentage increase of
Agg(1) relative to Agg(2).
FIG. 6. Effect of the serine protease inhibitor, AEBSF, on a-thrombin-induced platelet aggregation. Washed human concentrated
platelets (50 ml, Plts) were added to a-thrombin (0.025 units) plus fibrinogen (50 mg) (T 1 F) preincubated in a total of 430 ml of Hepes-Tyrode buffer
for 2 min at 37 °C in a stirring cuvette generating polymerizing fibrin (panel A). In panel B, 2.5 mM AEBSF (noted as A) was added at the same
time as a-thrombin and fibrinogen; in panel C, it was added after a-thrombin plus fibrinogen was preincubated for 2 min and 30 s, before the
addition of platelets. Aggregation was measured, and data for multiple experiments are reported as in Fig. 1.
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specific a-thrombin binding site, is a probable candidate. Since
SCH203099 and anti-PAR-1 antibodies had no effect on
g-thrombin-induced platelet aggregation and g-thrombin can-
not bind to or activate GP Ib (45), PAR-4 appears to be the
receptor sensitive to g-thrombin. These conclusions are in con-
cert with another recent report (46) that implicates the pres-
ence of three thrombin platelet receptors. Smith and Owens
(46) demonstrated that a-thrombin interacts with an uniden-
tified receptor other than PAR-1 and that b-thrombin (an au-
toproteolytic intermediate between a- and g- thrombin) inter-
acts with a receptor other then PAR-1. Our preliminary studies
indicate that b-thrombin, at least in part, acts at PAR-4 as we
demonstrate here with g-thrombin.
The proof that GP Ib is a functional thrombin receptor has
been difficult to establish (11, 12, 18–21). More conclusive
evidence comes from our current studies, which demonstrate
that the venom metalloproteinase, mocarhagin, that hydro-
lyzes the extracellular portion of GP Iba, abrogates a-throm-
bin-induced aggregation under appropriate conditions, and the
Fab fragment of the anti-GP Ib antibody, LJ Ib-10, that selec-
tively binds to the thrombin binding site completely blocks
a-thrombin-induced platelet aggregation under conditions
where the PAR-1 and PAR-4 receptors are nonfunctional.
Platelet activation via the thrombin-GP Ib pathway is quite
distinct from the PAR pathways. Thrombin must be bound to
GP Ib; however, based upon our results with AEBSF-inacti-
vated thrombin, platelet activation occurs in the absence of
hydrolysis of the receptor. This pathway requires polymerizing
fibrin and not the parent molecule, fibrinogen. Therefore, the
a-thrombin, bound to GP Ib, must remain catalytically active to
hydrolyze fibrinogen, but not the receptor itself, in order to
induce platelet aggregation via this pathway.
The requirement for polymerizing fibrin is clearly defined by
the series of studies where results are compared with thrombin
plus fibrinogen added to platelets versus platelets added to
polymerizing fibrin. The initial inhibition observed in Fig. 3, C
(a) and E (a), is in agreement with previous evidence that RGD
and the g-chain AGDV are required for fibrinogen binding to
GP IIb/IIIa activated via the PAR-1 pathway. The reversal of
inhibition with time (delayed platelet aggregation) indicates
that the alternate a-thrombin pathway, the GP Ib pathway, is
independent of RGD/g-peptide sequences. Platelet aggregation,
under our conditions, absolutely requires polymerizing fibrin
based upon the fact that fibrin monomers generated in the
presence of GPRP followed by the addition of RGDS do not
support aggregation, while RGDS alone can only delay the
reaction. Platelets preincubated with the potent inhibitors of
fibrinogen binding to GP IIb/IIIa, anti-GP IIb/IIIa antibody
c7E3 Fab or LJCP-8 (Refs. 5 and 10, respectively), aggregated
with the same kinetics as those treated with RGDS (data not
shown). These results further substantiate the independence of
the GP Ib pathway on the RGD/g peptide sequences. The con-
clusion that thrombin-GP Ib-induced aggregation, in the pres-
ence of RGDS, involves polymerizing fibrin instead of fibrino-
gen is also in agreement with the observation that RGDS
irreversibly blocks aggregation induced by U46619 or ADP,
since neither agonist can generate polymerizing fibrin.
The thrombin inhibitor, hirudin, completely blocks platelet
aggregation, whether it is added first to thrombin plus fibrin-
ogen, preventing the formation of polymerizing fibrin, or if it is
added after the formation of polymerizing fibrin but prior to the
addition of platelets. These results demonstrate that genera-
tion of polymerizing fibrin alone under our experimental con-
ditions is insufficient to induce aggregation or trapping of
platelets. Also, aggregation will not occur if a-thrombin cannot
bind to GP Ib, since hirudin blocks both the proteolytically
active and GP Ib-binding sites on thrombin, even when throm-
bin is complexed with fibrin (47). Further evidence that platelet
aggregation is not “platelet trapping” by the low levels of poly-
merizing fibrin employed here comes from the fact that these
activated platelets release ATP and mobilize internal stores of
Ca21. Both of these responses are coupled to ligand-induced
signal transduction, indicating that the polymerizing fibrin is
binding to a selective receptor. This is in sharp contrast to the
case where ristocetin-treated platelets are agglutinated/
trapped by vWF alone or by vWF plus polymerizing fibrin. No
ATP was released. Also, exposure of platelets to a-thrombin
plus fibrinogen in the absence of stirring was insufficient to
induce significant aggregation or ATP release although the
thrombin presumably was bound to the thrombin receptors
(data not shown). This excludes the possibility that the ob-
served ATP release in our experimental samples was due to
a-thrombin binding to a thrombin receptor(s) at the same time
platelets were being trapped in a fibrin clot. Some may argue
that the slower a-thrombin response to [Ca21]i mobilization in
the presence of SCH203099 is PAR-4 and not GP Ib. However,
the level of a-thrombin used in our experiments is 10–100-fold
lower than necessary to elicit a response presumably via PAR-4
in platelets pretreated with 30 mM SFLLRNP (16). Finally,
electron microscopic analysis of aggregated platelets under our
experimental conditions demonstrates that platelets are not
trapped in a fibrin network but undergo spreading and degran-
ulation expected in agonist-induced aggregation.
Others have also shown that fibrin-induced procoagulant
(thrombin generation) activity in platelets requires a GP IIb/
IIIa independent fibrin-integrin interaction (42). Loscalzo et al.
(43) reported that GP Ib could serve as a fibrin-vWF receptor
involved in the incorporation of platelets into fibrin thrombi.
The reaction was independent of GP IIb/IIIa. However, com-
parisons between our work and this group’s work are difficult,
if not impossible, since their experimental conditions were so
different from ours. They were not measuring platelet aggre-
gation but rather platelet association with the fibrin thrombi in
the presence of active protease (bovine, not human thrombin,
or Bothrops atrox venom) and a calcium chelator (10 mM
EDTA). Their reaction took place over a 20–30-min period at
25 °C. It is clear from our work that the association of polymer-
izing fibrin with the ristocetin-induced GP Ib-vWF complex can
be almost immediate under the appropriate conditions, result-
ing in the complete trapping of platelets in a clot. Therefore,
while there are interesting similarities to our observations, it is
not currently clear if this is just coincidence or perhaps over-
lapping mechanisms. Other reports have observed “deviant”
binding of fibrinogen/fibrin presumably to the GP IIb-IIIa com-
plex (48).
It is apparent that thrombin binding alone to GP Ib is not
sufficient to induce aggregation in the presence of fibrinogen,
as demonstrated by the total inhibition by AEBSF added prior
to the formation of polymerizing fibrin. AEBSF blocks the
catalytic site but not the binding site of thrombin. The fibrin-
ogen must be hydrolyzed by thrombin to produce polymerizing
fibrin. Thrombin bound to the extracellular portion of GP Ib,
glycocalicin, remains catalytically active (49, 50). It is possible
that under normal conditions this thrombin activates platelets
via a nonprotelolytic GP Ib pathway in conjunction with the
presentation of bound thrombin to activate platelets proteolyti-
cally via PAR-1 (18, 50) and/or PAR-4 pathways. The results of
our studies may explain observations made nearly a quarter of
a century ago with phenylmethlylsulfonyl fluoride-inactivated
thrombin, showing that the phenylmethlylsulfonyl fluoride-
thrombin complex bound to a platelet membrane site potenti-
ated the activity of a second proteolysis-dependent site (51).
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Others have shown that catalytically inactive thrombin (chem-
ically modified) bound to GP Ib inhibits the PAR-1 pathway
(46). This implies a spatial arrangement of the two receptors
such that the entry of a second, active thrombin molecule is
blocked from interacting with PAR-1, although antibody stud-
ies might argue against this. The ability of a-thrombin to bind
to and activate GP Ib and simultaneously activate PAR-1
and/or PAR-4 may explain the synergistic potential of these
three thrombin receptors at both the extracellular level in
addition to cross-talk between intracellular second messenger
pathways.
Thrombin-induced activation of PAR-1 results in an out-
side-in signal transduction process followed by the alteration of
the surface integrin, GP IIb/IIIa, by an inside-out signal (6).
The conformational change of GP IIb/IIIa leads to the Ca21-de-
pendent binding of the bifunctional fibrinogen molecule (7, 8).
It is hypothesized that the outside-in and/or inside-out signals
initiated by thrombin binding to GP Ib are different than the
thrombin-induced PAR-1 or PAR-4 signals. One possibility is
that the GP Ib-associated pathway induces a conformational
alteration of GP IIb/IIIa that binds polymerizing fibrin in pref-
erence to fibrinogen in a Ca21-dependent fashion at peptide
sites other than those commonly observed. This is consistent
with the concept that integrin affinities for ligands can be
modified by altered inside-out signals (52). A second, perhaps
more likely case is that the thrombin-GP Ib complex activates
a signal-transducing pathway that activates a different inte-
grin that selectively binds polymerizing fibrin. This latter case
is supported by studies with platelets derived from Glanzmann
thrombasthenic patients. These platelets lack a functional GP
IIb/IIIa complex yet were shown to effectively bind polymeriz-
ing fibrin in a Ca21-dependent manner (39). It is well estab-
lished that GP Ib is coupled to a different signal-transducing
pathway than PAR-1/4, at least in response to vWF (25–27).
Furthermore, it was shown that GP IIb/IIIa could be activated
in a transfected cell system, by an interaction of GP Ib with
vWF in the absence of GP V and actin-binding protein and with
GP Ib lacking the domain that binds 14-3-3 z (53). While the
mechanism of activation is unresolved, it is concluded that the
vWF-GP Ib signaling pathway is different from the thrombin-
induced pathway.
The dogma that fibrinogen and polymerizing fibrin both bind
to GP IIb/IIIa via the same peptide sequences during platelet
aggregation is based more on assumptions than proof. The
evidence that fibrinogen peptide sequences selectively associ-
ate with GP IIb/IIIa is irrefutable; however, this is not the case
for polymerizing fibrin. It is clear that polymerizing fibrin plays
a role in platelet aggregation and adhesion/agglutination. It
was presumed that its interaction was the same as fibrinogen,
and this presumption slowly became “fact” without proof. Our
studies demonstrate that polymerizing fibrin plays some role in
platelet aggregation via a pathway that is independent of fi-
brinogen. The polymerizing fibrin apparently can bind at dif-
ferent amino acid sequences and/or integrins from fibrinogen
based on our studies with several different antibodies and
peptide inhibitors. Anti-GP IIb/IIIa (aIIb/b3) and anti-av/b3
antibodies that block the fibrinogen binding site(s) as well as
peptide inhibitors had no effect on the thrombin-GP Ib-poly-
merizing fibrin pathway (data both shown and not shown).
These results are similar to those previously reported (48) for
platelet adhesion with flowing blood. Also, the anti-GP Ib an-
tibody, LJIb1, that binds to the vWF binding site (28) had no
effect on this pathway (data not shown), further indicating that
the GP Ib-polymerizing fibrin pathway does not involve a GP
Ib-vWF-fibrin complex. The site and binding parameters of
polymerizing fibrin is clearly very important but remains ob-
scure at this time. The fact that the anti-integrin antibodies
tested to date do not block polymerizing fibrin binding does not
exclude these integrins as potential binding sites. Other inte-
grin epitopes not recognized by these antibodies may remain
available for interactions with polymerizing fibrin.
Low concentrations of thrombin bound to fibrinogen/fibrin
remain catalytically active, even in the presence of endogenous
regulators such as anti-thrombin III and heparin (54). Such
conditions may exist at sites of high vascular shear forces that
periodically strip endothelial cells from the vascular wall (55).
These low levels of active thrombin, with or without other
potential platelet agonists, may be sufficient to activate the GP
Ib thrombin receptor to repair the localized damaged vessel
without triggering the more aggressive PAR-1 response. High
doses of hirudin administered in clinical trials to effectively
inhibit platelet-dependent arterial thrombosis and restenosis
also resulted in unacceptable bleeding episodes. These levels of
hirudin would inhibit both the PAR-1- and the GP Ib-thrombin-
activating pathways. When the hirudin dose was reduced suf-
ficiently to alleviate bleeding problems, the anti-thrombotic
effect was greatly reduced. Studies in a nonhuman primate
model demonstrated that hirudin coupled to a fibrin antibody
fragment F(ab9)2 was more effectively targeted to inhibit
thrombin than was the free hirudin (56). The indication is that
the fibrin-thrombin complex that we have shown to induce
platelet aggregation may be physiologically important. High
shear forces enhance platelet-induced hemostasis at sites of
vessel wall injury (57). GP Ib-vWF complexes play an impor-
tant role in platelet adhesion to the vascular wall (58, 59).
Given the fact that GP Ib has separate binding sites for vWF
and thrombin, it is possible that the binding of one ligand will
synergistically facilitate the binding of the other ligand to the
same GP Ib molecule or to a different GP Ib molecule. This
could enhance platelet activation in the presence of subopti-
mum levels of vWF and thrombin in a fashion similar to that
seen with other agonist pairs (60). Once the platelets are acti-
vated, they can express P-selectin, which would facilitate leu-
kocyte adhesion even under high shear forces that would oth-
erwise inhibit leukocyte adhesion (57). The deposition of
leukocytes under these conditions along with platelets could
also contribute to atherogenesis at localized regions of chronic
shear-induced vessel injuries.
Our studies demonstrate that human platelets respond to
a-thrombin via PAR-1 and GP Ib receptors through mecha-
nisms that are distinct in vitro and, presumably, in vivo. A
second PAR receptor, PAR-4 (15), does not appear to respond to
physiologic levels of a-thrombin but may be responsive to in
vivo generated g-thrombin based upon our in vitro observa-
tions. Furthermore, the synergistic effect of minimally acti-
vated thrombin receptors may have significant implications for
in vivo thrombotic events. The recently cloned PAR-3 (17) is
either absent or present in only trace amounts in human plate-
lets. The physiological role, if any, of PAR-3 and PAR-4 in
human platelets remains to be established. However, the equal
intensity of platelet responses observed in vitro with low levels
of a-thrombin acting on PAR-1 and GP Ib and the synergy
between GP Ib and PAR-1 and/or PAR-4 indicate that these
three thrombin receptors are candidates to function in vivo.
Multiple platelet thrombin receptors may reflect the physiolog-
ical requirement to respond differentially to varying concentra-
tions of a-, b-, and g-thrombins and/or to different presenta-
tions of thrombin complexed with other proteins. The presence
of GP Ib as a functional thrombin receptor, independent of
fibrinogen, along with its synergy with the g-thrombin-depend-
ent PAR-4 receptor may explain why anti-a-thrombin/anti-
platelet regimens fail to completely abrogate thrombosis/rest-
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enosis in the cardiac patient. Moreover, the identification of
selected conditions to study the thrombin response where one
pathway predominates over another opens the door to a more
complete understanding of the molecular mechanisms of action
of these pathways. It also affords an opportunity to evaluate
new drugs that may abrogate chronic pathologic responses to
thrombin in vivo.
A recent report (61), submitted and published while our
paper was in review, substantiates two aspects of our work
presented here with human platelets and previously published
as an abstract (62). Work with a Gp V null mouse showed that
GP Ib was in fact a functional thrombin receptor for platelet
aggregation. Furthermore, activation did not require a proteo-
lytically active form of thrombin (61). The mouse GP Ib path-
way appears to be dependent upon an inhibitable fibrin(ogen)-
GP IIb/IIIa interaction as opposed to what we observe with the
human GP Ib pathway. Future studies should help resolve this
and other differences between the GP Ib pathway in the two
species.
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